Porpodis Konstantinos, Tsiouprou Ioanna, Apostolopoulos Apostolos, Ntontsi Polyxeni, Fouka Evangelia, Papakosta Despoina, Vliagoftis Harissios, Domvri Kalliopi
Pulmonary Department, Aristotle University of Thessaloniki, George Papanikolaou Hospital, 57010 Thessaloniki, Greece.
2nd University Department of Respiratory Medicine, Attikon Hospital, 12462 Athens, Greece.
J Pers Med. 2022 Jun 30;12(7):1093. doi: 10.3390/jpm12071093.
Asthma phenotyping and endotyping are constantly evolving. Currently, several biologic agents have been developed towards a personalized approach to asthma management. This review will focus on different eosinophilic phenotypes and Th2-associated endotypes with eosinophilic inflammation. Additionally, airway remodeling is analyzed as a key feature of asthmatic eosinophilic endotypes. In addition, evidence of biomarkers is examined with a predictive value to identify patients with severe, uncontrolled asthma who may benefit from new treatment options. Finally, there will be a discussion on the results from clinical trials regarding severe eosinophilic asthma and how the inhibition of the eosinophilic pathway by targeted treatments has led to the reduction of recurrent exacerbations.
哮喘的表型分析和内型分析一直在不断发展。目前，已经开发了几种生物制剂，以实现哮喘管理的个性化方法。本综述将聚焦于不同的嗜酸性粒细胞表型以及与嗜酸性粒细胞炎症相关的Th2型内型。此外，气道重塑被分析为哮喘嗜酸性粒细胞内型的一个关键特征。此外，还研究了具有预测价值的生物标志物证据，以识别可能从新治疗方案中获益的重度、未控制哮喘患者。最后，将讨论关于重度嗜酸性粒细胞性哮喘的临床试验结果，以及靶向治疗对嗜酸性粒细胞途径的抑制如何导致复发加重的减少。
